A股異動 | 地塞米松概念股續漲 世衞稱地塞米松可降低重症患者死亡率
格隆匯6月18日丨地塞米松概念股續漲,龍頭股天藥股份連續第二日一字板,溢多利漲3.5%,現代製藥漲1.6%。據中國日報,週三,世界衞生組織總幹事譚德塞在疫情發佈會上分享了救治重症新冠病患的積極成果:類固醇藥物地塞米松在英國的臨牀試驗中,將接受吸氧治療的患者死亡率降低了約五分之一,將使用呼吸機的患者死亡率降低了約三分之一。此外,英國衞生部16日宣佈,即日起政府正式批准本國醫療體系使用地塞米松來治療醫院中那些需要吸氧以及使用呼吸機的新冠病患。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.